• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Cortice Biosciences, Inc. claimed ownership of 573,368 shares (SEC Form 3)

    8/6/24 4:53:41 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNSP alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Cortice Biosciences, Inc.

    (Last) (First) (Middle)
    1345 AVENUE OF THE AMERICAS, 42ND FLOOR

    (Street)
    NEW YORK NY 10105

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    07/29/2024
    3. Issuer Name and Ticker or Trading Symbol
    CNS Pharmaceuticals, Inc. [ CNSP ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 573,368 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Cortice Biosciences, Inc., /s/ Michael Weiser, Director 08/06/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CNSP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNSP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CNSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brookline Capital initiated coverage on CNS Pharmaceuticals with a new price target

      Brookline Capital initiated coverage of CNS Pharmaceuticals with a rating of Buy and set a new price target of $10.00

      2/2/21 10:31:34 AM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNSP
    SEC Filings

    See more
    • SEC Form 10-Q filed by CNS Pharmaceuticals Inc.

      10-Q - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

      5/15/25 5:00:20 PM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B4 filed by CNS Pharmaceuticals Inc.

      424B4 - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

      5/14/25 8:59:05 AM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by CNS Pharmaceuticals Inc.

      EFFECT - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

      5/14/25 12:15:38 AM ET
      $CNSP
      Biotechnology: Pharmaceutical Preparations
      Health Care